A third of patients in a clinical trial had tumors shrink while taking a genetically engineered treatment known as RP1.
Rigel Pharmaceuticals Inc. (NASDAQ:RIGL) stock is trading higher on Tuesday as the company is entering an exclusive global ...
Extended follow-up data from the phase 3 study (20 months after reported topline data, median follow-up 58 months) confirmed ...
Discusses Extended Follow-Up Data From Phase 3 Trial of aglatimagene besadenovec in Localized Prostate Cancer May 15, ...
Classy move by the Tigers, honoring late sportswriter Pat Caputo with a moment of silence Friday night at Comerica Park.
14h
Jackie Tohn Reveals She Had Double Mastectomy Due to Genetic Mutation — and Had Precancerous Cells
The “Nobody Wants This” actor initially struggled with the decision but is now raising awareness for genetic testing.
The “Nobody Wants This” star learned she was a carrier for the BRCA gene, a genetic mutation known for an increased risk of ...
Akeso, Inc. (9926.HK) ('Akeso' or the 'Company') today announced that compelling results from its randomized, double-blind, placebo-controlled Phase II trial (AK117-206) of ligufalimab (AK117) will be ...
FDA rejects melanoma drug vusolimogene with nivolumab, citing insufficient evidence from Replimune’s phase 2 and 3 trials.
Inhibrx Biosciences, Inc. (Nasdaq: INBX) ("Inhibrx" or the "Company") today reported financial results for the first quarter ...
A fundraiser and community car meet will be held May 17 in Roseburg to support Jarod Clark and his family as he continues a ...
Barbara said that while the family is heartbroken by the news, Hannah's bravery and positive attitude have been truly ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results